Craneware plc Grant of Options - Replacement (9459L)

TIDMCRW

RNS Number : 9459L

Craneware plc

07 October 2016

This replaces the 'Grant of Options' announcement released on 13 September 2016 at 14:48 under RNS No 7265J. The number of options granted was corrected to 36,469.

All other details remain unchanged.

The full amended version is shown below.

Craneware plc

("Craneware", "the Group" or the "Company")

Grant of Options

7 October 2016 - The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces that on 12 September 2016, the Remuneration Committee approved the granting of share options to certain Directors to subscribe for ordinary shares of 1p each in the Company as follows:

 
 Director         No. of options           Percentage of 
                         granted    issued share capital 
 Keith Neilson 
  (CEO)                   36,469                    0.14 
 
 

The above options have been granted at an exercise price of 1177.5p per share (being the closing market price on 12 September 2016). These options will be subject to performance criteria, such that they vest in three equal tranches over three years. One third of the share options will vest on or after 30 June 2017, one third on or after 30 June 2018 and the final third on or after 30 June 2019. The share options will not become exercisable until three years from the date of the grant.

 
 PDMR notification - Keith Neilson 
 1. Details of the Restricted Person / person 
  closely associated with him or her 
            a) Name                                      Keith Neilson 
 2. Reason for the notification 
            a) Position/status                           CEO 
            b) Initial notification /                    Initial notification 
             Amendment 
 3. Details of the issuer, emission allowance 
  market participant, auction platform, auctioneer 
  or auction monitor 
            a) Name                                      Craneware plc 
            b) LEI                                       213800O2CTJ1YFXNXG05 
 4. Details of the transaction(s): section to 
  be repeated for (i) each type of instrument; 
  (ii) each type of transaction; (iii) each date; 
  and (iv) each place where transactions have been 
  conducted 
            a) Description of the financial              Ordinary shares of 
             instrument, type of instrument               1p each in the capital 
                                                          of Craneware plc 
            b) Identification code                       ISIN GB00B2425G68 
            c) Nature of the transaction                 Grant of options 
            d) Price(s) and volume(s)                    Volume(s) granted 
                                                          36,469 
                                                          Price(s) n/a 
                           e) Aggregated information:    Aggregate volume granted 
                            i. Aggregated volume          36,469 
                            ii. price                     Price(s) n/a 
            f) Date of the transaction                   2016-09-12 
            g) Place of the transaction                    London Stock Exchange (XLON); AIM 
 

For further information, please contact:

 
 Craneware plc    Peel Hunt          Alma 
 [phone]   [phone]     [phone] 
  3100             8900               4218 
 Keith Neilson,   Dan Webster        Caroline Forde       , 
  CEO 
 Craig Preston,   Adrian Trimmings   Hilary Buchanan 
  CFO              George Sellar      Robyn McConnachie 
 
 

About Craneware

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

Craneware is the leader in automated value cycle solutions that help US provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston and Phoenix employing over 200 staff. Craneware's market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFSSEFMFMSEDS

(END) Dow Jones Newswires

October 07, 2016 02:00 ET (06:00 GMT)